SaaS Metrics
Academic Publication Allogeneic CD19-targeted CAR-T therapy in patients with severe myositis and systemic sclerosis
AI Semantic Synergy Context
Connecting this academic literature to real-world market discussions and products.
Allogeneic CD19-targeted CAR-T therapy in patients with severe myositis and systemic sclerosis
No description provided.
Deep phenotyping of skin tissue remodeling in patients with systemic sclerosis treated with CD19-CAR T cells
CD19-specific chimaeric antigen receptor (CAR) T cell therapy has recently been evaluated for the treatment of systemic sclerosis (SSc). Here, the authors use multiomic analyses to demonstrate that...
In vivo CAR T cell generation to treat cancer and autoimmune disease
Chimeric antigen receptor (CAR) T cell therapies have transformed treatment of B cell malignancies. However, their broader application is limited by complex manufacturing processes and the necessit...
In Medical First, a Single Therapy Knocked Out 3 Autoimmune Diseases at Once
CAR T-cell therapy could help tackle the most severe cases that haven't responded to other treatments, her doctors say. ALT DEK: 14 months later, the woman still doesn't need any treatments for h...
Evolving understanding of autoimmune mechanisms and new therapeutic strategies of autoimmune disorders
Abstract Autoimmune disorders are characterized by aberrant T cell and B cell reactivity to the body’s own components, resulting in tissue destruction and organ dysfunction. Autoi...
Frequently Asked Questions (FAQ)
Curated market intelligence mapped to this research.
What is the core focus of the research titled 'Allogeneic CD19-targeted CAR-T therapy in patients with severe myositis and systemic sclerosis'?
This literature focuses on:
What other academic literature is closely related to 'Allogeneic CD19-targeted CAR-T therapy in patients with severe myositis and systemic sclerosis'?
Yes, highly correlated activity was mapped. An entry titled 'Allogeneic CD19-targeted CAR-T therapy in patients with severe myositis and systemic sclerosis' discusses this: No description provided.
Are there commercial applications of 'Allogeneic CD19-targeted CAR-T therapy in patients with severe myositis and systemic sclerosis' in market news publications?
Yes, highly correlated activity was mapped. An entry titled 'Deep phenotyping of skin tissue remodeling in patients with systemic sclerosis treated with CD19-CAR T cells' discusses this: CD19-specific chimaeric antigen receptor (CAR) T cell therapy has recently been evaluated for the treatment of systemic sclerosis (SSc). Here, the ...
Cite this Market Intelligence Report
Reference our AI-mapped synergy between this research and the commercial market to instantly build authority.